{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:17:10Z","timestamp":1740107830892,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jiac.2024.06.003","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:15:19Z","timestamp":1718230519000},"page":"1266-1273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and clinical characteristics of people with HIV with limited treatment options in Japan: A Japanese claims data analysis"],"prefix":"10.1016","volume":"30","author":[{"given":"Keisuke","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Piao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KuanYeh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Mezzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Gatanaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.06.003_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174360","article-title":"The hiv care cascade: Japanese perspectives","volume":"12","author":"Iwamoto","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2024.06.003_bib3","unstructured":"WHO Expert Consultation. Art failure and strategies for switching art regimens in the who european region. Report of the WHO expert consultation. Copenhagen."},{"key":"10.1016\/j.jiac.2024.06.003_bib4","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1089\/aid.2006.0310","article-title":"Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz","volume":"23","author":"Borroto-Esoda","year":"2007","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jiac.2024.06.003_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/09540121.2012.712667","article-title":"The impact of specific hiv treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis","volume":"25","author":"Al-Dakkak","year":"2013","journal-title":"AIDS Care"},{"key":"10.1016\/j.jiac.2024.06.003_bib6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"Hiv-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2024.06.003_bib7","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2666-5247(20)30006-9","article-title":"Pan-resistant hiv-1 emergence in the era of integrase strand-transfer inhibitors: a case report","volume":"1","author":"Puertas","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jiac.2024.06.003_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa456","article-title":"Burden of disease in pwh harboring a multidrug-resistant virus: data from the prestigio registry","volume":"7","author":"Galli","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2024.06.003_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12879-023-08038-w","article-title":"Heavily treatment-experienced people living with hiv in the opera(r) cohort: population characteristics and clinical outcomes","volume":"23","author":"Hsu","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2024.06.003_bib10","series-title":"The 22nd international AIDS conference. Amsterdam, The Netherlands","article-title":"Identifying heavily treatment-experienced patients in the opera cohort","author":"Hsu","year":"2018"},{"key":"10.1016\/j.jiac.2024.06.003_bib11","unstructured":"Henegar C., Vannappagari V., Viswanathan S., DeKoven M., Clark A., Ackerman P., Llamoso C. Identifying heavily treatment-experienced patients in a large administrative claims database. 10th IAS conference on HIV science. Mexico city, Mexico; 2019."},{"key":"10.1016\/j.jiac.2024.06.003_bib12","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","article-title":"Substantial decline in heavily treated therapy-experienced persons with hiv with limited antiretroviral treatment options","volume":"34","author":"Bajema","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2024.06.003_bib13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/QAI.0000000000002635","article-title":"Prevalence and outcomes for heavily treatment-experienced individuals living with human immunodeficiency virus in a european cohort","volume":"87","author":"Pelchen-Matthews","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2024.06.003_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab562","article-title":"Characterization of heavily treatment-experienced people with hiv and impact on health care resource utilization in us commercial and medicare advantage health plans","volume":"8","author":"Priest","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2024.06.003_bib15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jiac.2022.07.005","article-title":"Real-world medication persistence among hiv-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan","volume":"28","author":"Wang","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.06.003_bib16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1186\/s12879-019-4129-6","article-title":"Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database","volume":"19","author":"Ruzicka","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2024.06.003_bib17","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41598-022-05816-5","article-title":"Analysis of antiretroviral therapy switch rate and switching pattern for people living with hiv from a national database in Japan","volume":"12","author":"Naito","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2024.06.003_bib18","unstructured":"Medical data vision Co., Ltd. MDV ebm insight https:\/\/www.mdv.co.jp\/ebm\/. [Accessed 4 July 2023]."},{"key":"10.1016\/j.jiac.2024.06.003_bib19","unstructured":"Ministry of education, culture, sports, science and technology, Ministry of health, labour and welfare, Ministry of economy, trade and industry. Ethical guidelines for medical and biological research involving human subjects. 2021. https:\/\/www.mhlw.go.jp\/content\/001077424.pdf. [Accessed 13 March 2024]."},{"key":"10.1016\/j.jiac.2024.06.003_bib20","unstructured":"The European Pharmaceutical Market Research Association (EPHMRA). Ephmra anatomical classification guidelines 2023. https:\/\/www.ephmra.org\/sites\/default\/files\/2023-01\/2023%20ATC%20Guidelines%20Final_0.pdf. [Accessed 13 April 2023] 2023."},{"key":"10.1016\/j.jiac.2024.06.003_bib21","article-title":"Real world data on forgiveness to uncomplete adherence to bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"21","author":"Maggiolo","year":"2022","journal-title":"J Int Assoc Phys AIDS Care"},{"author":"Nau","key":"10.1016\/j.jiac.2024.06.003_bib22"},{"year":"2007","series-title":"Using arrays to calculate medication utilization","author":"Leslie","key":"10.1016\/j.jiac.2024.06.003_bib23"},{"key":"10.1016\/j.jiac.2024.06.003_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/hiv.13206","article-title":"Comorbidities and co-medications among 28 089 people living with hiv: a nationwide cohort study from 2009 to 2019 in Japan","volume":"23","author":"Naito","year":"2022","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2024.06.003_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019985","article-title":"Comorbidities and the use of comedications in people living with hiv on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database","volume":"8","author":"Ruzicka","year":"2018","journal-title":"BMJ Open"},{"year":"2023","series-title":"Quarterly report","key":"10.1016\/j.jiac.2024.06.003_bib26"},{"key":"10.1016\/j.jiac.2024.06.003_bib27","article-title":"Study on nationwide healthcare delivery system for hemophilia patients complicated by hiv infection","author":"Noda","year":"2021","journal-title":"Research Report for Grant for Scientific Research on Health, Labour and Welfare (AIDS policy research project)"},{"key":"10.1016\/j.jiac.2024.06.003_bib28","series-title":"The 37th annual meeting of the Japanese society for AIDS research. Kyoto, Japan","article-title":"Adherence to b\/f\/taf treatment and clinical outcome: an analyis of the Japanese claims database","author":"Naito","year":"2023"},{"key":"10.1016\/j.jiac.2024.06.003_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(06)70550-3","article-title":"Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced hiv-positive adults","volume":"6","author":"Temesgen","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2024.06.003_bib30","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an hiv-1 fusion inhibitor, for drug-resistant hiv infection in north and south America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.06.003_bib31","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant hiv-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.06.003_bib32","first-page":"180","article-title":"Antiretroviral salvage therapy for multiclass drug-resistant hiv-1-infected patients: from clinical trials to daily clinical practice","volume":"13","author":"Imaz","year":"2011","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jiac.2024.06.003_bib33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","volume":"368","author":"Hicks","year":"2006","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jiac.2024.06.003_bib34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/14787210.3.5.815","article-title":"Treatment strategies for highly treatment-experienced hiv-infected patients","volume":"3","author":"Luber","year":"2005","journal-title":"Expert Rev Anti-infect Ther"},{"key":"10.1016\/j.jiac.2024.06.003_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/01.qai.0000185314.56556.c3","article-title":"Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced hiv-1-infected patients in the t-20 versus optimized background regimen only 1 and 2 clinical trials","volume":"40","author":"Nelson","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2024.06.003_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/dkm522","article-title":"What is the risk of mortality following diagnosis of multidrug-resistant hiv-1?","volume":"61","author":"Grover","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.06.003_bib37","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/01.aids.0000174455.01369.ad","article-title":"Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of hiv-infected patients","volume":"19","author":"Zaccarelli","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2024.06.003_bib38","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1080\/13696998.2021.1995868","article-title":"Retrospective analysis of adherence to hiv treatment and healthcare utilization in a commercially insured population","volume":"24","author":"Priest","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.jiac.2024.06.003_bib39","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","article-title":"Real-world adherence to antiretroviral therapy among hiv-1 patients across the United States","volume":"38","author":"McComsey","year":"2021","journal-title":"Adv Ther"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24001582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24001582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:56:33Z","timestamp":1738716993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24001582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1341321X24001582"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.06.003","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and clinical characteristics of people with HIV with limited treatment options in Japan: A Japanese claims data analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}